Moody Lynn & Lieberson LLC Purchases New Position in Regeneron Pharmaceuticals

Institutional investor buys 3,350 shares of biotech company in Q4 2025

Apr. 1, 2026 at 10:25am

Got story updates? Submit your updates here. ›

Moody Lynn & Lieberson LLC, an institutional investor, purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter of 2025, according to a recent SEC filing. The firm acquired 3,350 shares of the biopharmaceutical company's stock, valued at approximately $2.59 million.

Why it matters

Regeneron Pharmaceuticals is a major player in the biotech industry, known for its innovative drug discovery technologies and pipeline of biologic therapies. This new investment by Moody Lynn & Lieberson LLC suggests institutional confidence in the company's long-term growth potential.

The details

The filing shows that Moody Lynn & Lieberson LLC purchased the 3,350 shares of Regeneron Pharmaceuticals during the fourth quarter of 2025. This adds to the firm's overall position in the biotech company, which is part of a broader investment strategy focused on the healthcare sector.

  • Moody Lynn & Lieberson LLC purchased the Regeneron Pharmaceuticals shares in the fourth quarter of 2025.

The players

Moody Lynn & Lieberson LLC

An institutional investment firm that purchased a new position in shares of Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This investment by Moody Lynn & Lieberson LLC underscores the institutional confidence in Regeneron Pharmaceuticals' long-term growth prospects within the biotech industry. As the company continues to advance its pipeline of innovative therapies, it will be closely watched by investors seeking exposure to the healthcare sector.